AURA NASDAQ
Aura Biosciences, Inc.
1W: -4.1%
1M: +2.1%
3M: +41.4%
YTD: +44.3%
1Y: +29.0%
3Y: -30.1%
$7.60
-0.05 (-0.65%)
Weekly Expected Move ±12.5%
$6
$7
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$487.9M
52W Range4.73-9.535
Volume269,510
Avg Volume464,147
Beta0.37
Dividend—
Analyst Ratings
Company Info
CEOElisabet de los Pinos
Employees106
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-29
Websiteaurabiosciences.com
85 Bolton Street
Boston, MA 02140
US
Boston, MA 02140
US
617 500 8864
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Latest News
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
Aura Biosciences prices $260M stock, warrant offering
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Holles Natalie C. | A-Award | 600,118 | — | 2026-05-19 |
| Holles Natalie C. | A-Award | 553,844 | — | 2026-05-19 |
| Holles Natalie C. | A-Award | 2,169,103 | $7.39 | 2026-05-19 |
| Matrix Capital Manag | S-Sale | 6,922,870 | $5.64 | 2026-05-07 |
| Holles Natalie C. | 0 | — | 2026-04-30 |